NEW YORK – German rare disease company Centogene on Thursday reported a 13 percent year-over-year revenue decrease in Q3 caused mainly by non-recurring upfront payments by two pharmaceutical partners a year ago.
"We're driving solid performance that is much better than what it might appear on paper," said Centogene CEO Arndt Rolfs during a conference call to discuss the financial results.